Wedbush keeps Outperform on Xencor and ORIC Pharmaceuticals
Wedbush reiterated Outperform ratings on Xencor and ORIC Pharmaceuticals, with price targets of $45 and $14, according to TradingView citing Benzinga data.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Wedbush kept its Outperform rating on Xencor with a $45 price target. According to TradingView, which cites Benzinga data, the target implies a 54.2% gain from the October 26 close of $29.18. Analysts pointed to a confirmed 45% overall response rate for XmAb819 in heavily pretreated patients with clear cell renal cell carcinoma, along with plans for a global randomized study and FDA discussions on accelerated approval.
For ORIC Pharmaceuticals, Wedbush also retained Outperform with a $14 target, implying a 56.3% upside from the $8.96 close. The note cited early data for ORIC-944 and ORIC-114, including an 88% disease control rate, even as the firm adjusted its price targets.
why it matters
Notes like these are routine coverage for small biotech names. They can move shares briefly, but they reflect one brokerage's view of trial data rather than a regulatory decision or a company announcement. Investors typically watch the trial milestones and FDA steps the note refers to.
tags
instruments
sources
- Wedbush maintains Outperform rating on Xencor, $45 price target — TradingView, 27 October 2026 at 13:12 UTC
- Wedbush maintains Outperform rating on ORIC Pharmaceuticals, $14 price target — TradingView, 27 October 2026 at 13:21 UTC
- RBC Capital maintains Outperform rating on Xencor, $43 price target — TradingView, 27 October 2026 at 14:11 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗